Investment Rating - The report maintains a "Buy" rating for the company [1][7] Core Insights - The company has made significant progress in its core pipeline, with multiple clinical data readouts expected this year, particularly for its HER2 ADC product, DB-1303, which has successfully reached the primary endpoint in a Phase III trial for HER2+ breast cancer and has submitted a marketing application [4][5] - The company reported a revenue of 1.852 billion yuan for 2025, a decrease of 4.6% year-on-year, primarily due to delays in milestone revenues from core products [3][9] - The company has a strong cash position with 3.325 billion yuan in cash and bank deposits, and has maintained positive operating cash flow for three consecutive years [3][9] Financial Projections - Revenue projections for the company are as follows: 1.774 billion yuan in 2026, 1.603 billion yuan in 2027, and 2.146 billion yuan in 2028, with a notable growth rate of 34% expected in 2028 [7][9] - The company is projected to have a diluted EPS of -28.79 yuan in 2025, improving to -4.18 yuan by 2028 [9][11] - The estimated reasonable market capitalization is 38.365 billion yuan, corresponding to a target price of 425.63 yuan per share [7]
映恩生物-B：映恩生物：核心管线加速全球开发，HER2 ADC 有望商业化-20260331